Bioniz Therapeutics is an emerging biopharmaceutical company leading the discovery and development of first-in-class peptide therapeutics that selectively and simultaneously inhibit multiple cytokines to treat immuno-inflammatory diseases and cancer.

Originating in research conducted at the National Institutes of Health (NIH), Bioniz is leveraging its expertise in cytokine biology to create a new class of therapeutics that will tackle the issue of cytokine redundancy. Cytokine redundancy refers to how the immune system uses multiple cytokines sharing overlapping functions to prevent immune system failures from single cytokine malfunctions. This is an evolutionary strategy that makes the immune system more resilient and robust. While this strategy is most often adaptive, cytokine redundancy is also the reason that highly effective immune therapy regimens are so difficult to develop. Bioniz is changing that.